SCHEMBL2255161

SCHEMBL2255161

Fc1ccc(-c2cn3nc(NCc4ccc[nH]4)sc3n2)cc1Cl

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
F2RL3 Q96RI0 7/20 0.42
MAPT P10636 5/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
TP53 P04637 4/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
ABL1 P00519 1/20 0.37
FYN P06241 2/20 0.36
LMNA P02545 1/20 0.35
KDM4E B2RXH2 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TRPA1 O75762 1/20 0.34
PKM P14618 1/20 0.34
ALOX15 P16050 1/20 0.34
RECQL P46063 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1944803 0.85 NR1H4 (0.48) F2RL3MAPTSMN1; SMN2TP53NPC1
SCHEMBL1945114 0.82 FYN (0.44) F2RL3MAPTSMN1; SMN2TP53NPC1
SCHEMBL15603233 0.82 FYN (0.44) F2RL3MAPTSMN1; SMN2TP53NPC1
SCHEMBL1945663 0.81 FYN (0.43) F2RL3MAPTSMN1; SMN2TP53NPC1
SCHEMBL1944633 0.81 MAPT (0.46) F2RL3MAPTSMN1; SMN2TP53NPC1
SCHEMBL1947245 0.80 FYN (0.52) F2RL3MAPTSMN1; SMN2FYNLMNA
SCHEMBL2253070 0.80 F2RL3 (0.46) F2RL3MAPTSMN1; SMN2TP53NPC1
SCHEMBL2255151 0.80 FYN (0.57) FYN
SCHEMBL1946848 0.80 TP53 (0.48) F2RL3MAPTSMN1; SMN2TP53NPC1
SCHEMBL1945828 0.79 MAPT (0.40) F2RL3MAPTSMN1; SMN2TP53NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2193133-B1 IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN KINASE INHIBITORS FUNDACIÓN CT NAC DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (ES) 2015-08-19 EP disclosed
US-8563550-B2 Imidazolothiadiazoles for use as protein kinase inhibitors CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) 2013-10-22 US disclosed
US-20110190289-A1 Imidazolothiadiazoles for Use as Protein Kinase Inhibitors CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2011-08-04 US disclosed
EP-2193133-A2 IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN KINASE INHIBITORS Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) 2010-06-09 EP disclosed
WO-2009040552-A2 SUBSTITUTED IMIDAZO (2, 1-B) -1, 3, 4-THIAZOLE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES THEREOF CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) 2009-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190289-A1 Imidazolothiadiazoles for Use as Protein Kinase Inhibitors PIM1, PIM3, PIM2 F2RL3 3047/4885MAPT 3189/4885SMN1; SMN2 3346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.